Jason Fontenot - Sangamo Therapeutics Senior Vice President Cell Therapy
| SGMO Stock | USD 0.96 0.04 4.00% |
President
Dr. Jason Fontenot, Ph.D. is Senior Vice President, Cell Therapy of the Company. Dr. Fontenot has expertise in lymphocyte biology, cell engineering and immunemediated disease. The seminal work on regulatory T cells and FOXP3 conducted by Dr. Fontenot and his colleagues transformed the study of immune regulation and produced some of the most highly cited immunology publications of the last 20 years. In addition to his scientific expertise, Dr. Fontenot has an extensive background in drug development. Before joining Sangamo, he served as Chief Scientific Officer at Immusoft, leading the development of the company engineered B cell therapy platform. Prior to Immusoft, Dr. Fontenot served as Head of Exploratory Research at Juno Therapeutics, where he was responsible for advancing the early stage engineered T cell therapy pipeline and overseeing the development of next generation cellular engineering strategies. Before joining Juno, Dr. Fontenot worked for nearly a decade as a group leader in the immunology department at Biogen, where his team focused on T cell biology and immune regulation since 2019.
| Age | 54 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 501 Canal Blvd, Richmond, CA, United States, 94804 |
| Phone | 510 970 6000 |
| Web | https://www.sangamo.com |
Jason Fontenot Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jason Fontenot against Sangamo Therapeutics stock is an integral part of due diligence when investing in Sangamo Therapeutics. Jason Fontenot insider activity provides valuable insight into whether Sangamo Therapeutics is net buyers or sellers over its current business cycle. Note, Sangamo Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sangamo Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jason Fontenot over six months ago Disposition of 1029 shares by Jason Fontenot of Sangamo Therapeutics at 0.77 subject to Rule 16b-3 |
Sangamo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5829) % which means that it has lost $0.5829 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9405) %, meaning that it created substantial loss on money invested by shareholders. Sangamo Therapeutics' management efficiency ratios could be used to measure how well Sangamo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of February 2025, Return On Tangible Assets is likely to grow to -1.7. In addition to that, Return On Capital Employed is likely to grow to -2.55. At this time, Sangamo Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 26th of February 2025, Asset Turnover is likely to grow to 1.29, while Other Assets are likely to drop 1.09.Similar Executives
| Found 4 records | PRESIDENT Age | ||
| Kevin Fitzgerald | Alnylam Pharmaceuticals | 57 | |
| Edward III | Intellia Therapeutics | 48 | |
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Laura SeppLorenzino | Intellia Therapeutics | 63 | |
Management Performance
| Return On Equity | -1.94 | ||||
| Return On Asset | -0.58 |
Sangamo Therapeutics Leadership Team
Elected by the shareholders, the Sangamo Therapeutics' board of directors comprises two types of representatives: Sangamo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sangamo. The board's role is to monitor Sangamo Therapeutics' management team and ensure that shareholders' interests are well served. Sangamo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sangamo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Fontenot, Senior Vice President Cell Therapy | ||
| Phillip Ramsey, Head Operations | ||
| David Ojala, Scientist Research | ||
| Mark McClung, Ex COO | ||
| Stephanie CLP, Head Management | ||
| Whitney Jones, VP Officer | ||
| Andrew Ramelmeier, Ex Operations | ||
| Scott Willoughby, General VP | ||
| Gregory Davis, Head Technology | ||
| Lisa MD, Chief Officer | ||
| Aron Feingold, Head Officer | ||
| Amy Pooler, Head Research | ||
| ChB MB, Pres CEO | ||
| Heather Erickson, Chief Staff | ||
| Nathalie DuboisStringfellow, Senior Officer | ||
| Louise Wilkie, Vice Communications |
Sangamo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sangamo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.94 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (94.13) % | ||||
| Current Valuation | 197.17 M | ||||
| Shares Outstanding | 208.22 M | ||||
| Shares Owned By Insiders | 2.38 % | ||||
| Shares Owned By Institutions | 38.53 % | ||||
| Number Of Shares Shorted | 24.33 M | ||||
| Price To Earning | (15.31) X | ||||
| Price To Book | 5.33 X |
Pair Trading with Sangamo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Sangamo Stock
| 0.82 | GANX | Gain Therapeutics | PairCorr |
| 0.73 | CUE | Cue Biopharma | PairCorr |
| 0.72 | PHGE | Biomx Inc | PairCorr |
| 0.68 | OPT | Opthea Earnings Call Today | PairCorr |
| 0.66 | LTRN | Lantern Pharma | PairCorr |
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.